Publication Cover
Advances in Applied Ceramics
Structural, Functional and Bioceramics
Volume 110, 2011 - Issue 8: Cement and Concrete Research
88
Views
12
CrossRef citations to date
0
Altmetric
OriginalArticle

Injectable and bioresorbable calcium phosphate delivery system with gentamicin sulphate for treatment of bone diseases: in vitro study

, , , &
Pages 482-489 | Received 10 Jul 2011, Accepted 07 Sep 2011, Published online: 22 Nov 2013

References

  • Nelson CL: ‘The current status of material usedfor depot delivery of drugs’,Clin. Orthop. Relat.Res., 2004, 1, 72–78.
  • Goldstein SA, Moalli MR: ‘Current concepts in tissue engineering:cell, matrices, and genes’,Curr. Opin. Orthop., 2001, 12, 424–427.
  • Lu L, Currier BL, Yaszemsk MJ: ‘Synthetic bone substitutes’,Curr.Opin. Orthop., 2000, 11, 383–390.
  • Baksh D, Davies JE, Kim S: ‘Three-dimensional matrices of calciumpolyphosphates support bone growth in vitro and in vivo’,J.Mater. Sci., Mater. Med., 1998, 9, 743–748.
  • Kurashina K, Kurita H, Hirano M, Kotani A, Klein CP, de Groot K: ‘In vivo study of calcium phosphatecements: implantation of an alpha-tricalcium phosphate/dicalcium phosphatedibasic/tetracalcium phosphate monoxide cement paste’,Biomaterials, 1997, 18, 539–543.
  • Zamanian A, Moztarzadeh F, Kordestani S, Hesaraki S, Tahriri MR: ‘Novel calcium hydroxide/nanohydroxyapatitecomposites for dental applications: in vitro study’,Adv.Appl. Ceram., 2010, 109, 440–445.
  • Rabiee SM, Moztarzadeh F, Salimi-Kenari H, Solati-Hashjin M, Mortazavi SMJ: ‘Study of biodegradable ceramic bonegraft substitute’,Adv. Appl. Ceram., 2008, 107, 199–202.
  • Bolarinwa A, Gbureck U, Purnell P, Bold M, Grover ML: ‘Cement casting of calcium pyrophosphatebased bioceramics’,Adv. Appl. Ceram., 2010, 109, 291–295.
  • Apelt D, Theiss F, El-Warrak AO, Zlinszky K, Bettschart-Wolfisberger R, Bohner M, Matter S, Auer JA, von Rechenberg B: ‘In vivo behavior of three differentinjectable hydraulic calcium phosphate cements’,Biomaterials, 2004, 25, 1439–1451.
  • Jansen JA, de Ruijter JE, Schaeken HG, Waerden JPCvan der, Planell JA, Driessens FC: ‘Evaluation of tricalcium phosphate/hydroxyapatitecement for tooth replacement: an experimental anomaly study’,J.Mater. Sci., Mater. Med., 1995, 6, 653–657.
  • Friedman CD, Costantino PD, Takagi S, Chow LC: ‘BoneSource™ hydroxyapatitecement: a novel biomaterial for craniofacial skeletal tissue engineering andreconstruction’,J. Biomed. Mater. Res. A, 1998, 43A, 428–432.
  • Larsson S, Bauer TW: ‘Use of injectable calcium phosphatecement for fracture fixation – a review’,Clin.Orthop. Relat. Res., 2002, 395, 23–32.
  • Ooms EM, Wolke JGC, Heuvel MTvan de, Jeschke B, Jansen JA: ‘Histological evaluation of the boneresponse to calcium phosphate cement implanted in cortical bone’,Biomaterials, 2003, 24, 989–1000.
  • Ginebra M, Traykova T, Planell JA: ‘Calcium phosphate cements: competitivedrug carriers for the musculoskeletal system?’Biomaterials, 2006, 27, 2171–2177.
  • Arkfield DG, Rubenstein E: ‘Quest for the Holy Grail to cure arthritisand osteoporosis: emphasis on bone drug delivery systems’,Adv.Drug Delivery Rev., 2005, 57, 934–944.
  • Ginebra MP, Traykova T, Planell JA: ‘Calcium phosphate cements as bone drugdelivery systems: a review’,J. Controlled Release, 2006, 113, 102–110.
  • Brown PW, Chow LC: ‘A calcium phosphate water setting cement.Cements research progress’, Proc. AmericanCeramics Society, Cocoa Beach, FL, USA, 1986, ACS, 352–379.
  • Mirtchi AA, Lemaitre J: ‘Calcium phosphate cements: study ofthe β-tricalcium phosphate-monocalcium phosphate system’,Biomaterials, 1989, 10, 475–480.
  • Driessens FC, Boltong MG, Bermudez O, Planell JA, Ginebra MP, Fernandez E: ‘Effective formulations for the preparationof calcium phosphate bone cements’,J. Mater.Sci., Mater. Med., 1994, 5, 164–170.
  • Bermudez O, Boltong MG, Driessens FC, Planell JA: ‘Development of an octocalcium phosphatecement’,J. Mater. Sci., Mater. Med., 1994, 5, 144–146.
  • Dorozhkin SV: ‘Calcium orthophosphates as bioceramics:state of the art’,J. Funct. Biomater., 2010, 1, 22–107.
  • Khairoun I, Boltong MG, Driessens FC, Planell JA: ‘Limited compliance of some apatiticcalcium phosphate cements with clinical requirements’,J.Mater. Sci., Mater. Med., 1998, 9, 667–671.
  • Takagi S, Chow LC, Ishikawa K: ‘Formation of hydroxyapatite in newcalcium phosphate cements’,Biomaterials, 1998, 19, 1593–1599.
  • Knaack D, Aiolova M, Tofighi A, Catalano A, Rey C, Nies B, Lee DD: ‘a-BSMTM: a resorbable apatiticcalcium phosphate bone substitute’,Bioceramics, 1998, 11, 357–361.
  • Knaack D, Goad ME, Aiolova M, Rey C, Tofighi A, Chakravarthy P, Lee DD: ‘Resorbable calcium phosphate bone substitute’,J.Biomed. Mater. Res., 1998, 43, 399–409.
  • Ohura K, Bohner M, Hardouin P, Lemaitre J, Pasquier G, Flautre B: ‘Resorption of, and bone formation from,new beta-tricalcium phosphate-monocalcium phosphate cements: an in vivo study’,J.Biomed. Mater. Res., 1996, 30, 193–200.
  • Lemaitre J, Mirtchi AA, Mortier A: ‘Calcium phosphate cements for medicaluse: state of the art and perspectives of development’,Sil.Ind. Ceram. Sci., 1987, 10, 141–146.
  • Grover LM, Knowles JC, Fleming GJP, Barralet JE: ‘In vitro ageing of brushite calciumphosphate cement’,Biomaterials, 2003, 24, 4133–4141.
  • Takechi M, Miyamoto Y, Ishikawa K, Nagayama M, Kon M, Asaoka K: ‘Effects of added antibiotics on thebasic properties of anti-washout-type fast-setting calcium phosphate cement’,J.Biomed. Mater. Res., 1998, 39, 308–316.
  • Armstrong MS, Spencer RF, Cunningham JL, Gheduzzi S, Miles AW, Learmonth ID: ‘Mechanical characteristics of antibiotic-ladenbone cement’,Acta Orthop. Scand., 2002, 73, 688–690.
  • Gbureck U, Probst J, Thull R: ‘Surface properties of calcium phosphateparticles for self-setting bone cements’,Biomol.Eng., 2002, 19, 51–55.
  • Marks KE, Nelson CL, Lautenschlager EP: ‘Antibiotic-impregnated acrylic bonecement’,J. Bone Joint Surg. Am., 1976, 58, 358–364.
  • Walenkamp GH, Kleijn LL, de Leeuw M: ‘Osteomyelitis treated with gentamicin-PMMAbeads: 100 patients followed for 1–12 years’,ActaOrthop. Scand., 1998, 69, 518–522.
  • Hill J, Klenerman L, Trustey S, Blowers R: ‘Diffusion of antibiotics from acrylicbone-cement in vitro’,J. Bone Joint Surg. Br., 1977, 59, 197–199.
  • Faber C, Stallmann HP, Lyaruu DM, Joosten U, von Eiff C, Amerongen Avan Nieuw, Wuisman PI: ‘Comparable efficacies of the antimicrobialpeptide human lactoferrin 1–11 and gentamicin in a chronic methicillin-resistantstaphylococcus aureus osteomyelitis model’,Antimicrob.Agents Chemother., 2005, 49, 2438–2444.
  • Langer R: ‘Drug delivery and targeting’,Nature, 1998, 392, 5–10.
  • Wu Y, Mackay JA, Mcdaniel JR, Chilkoti A, Clark RL: ‘Fabrication of elastin-like polypeptidenanoparticles for drug delivery by electrospraying’,Biomacromolecules, 2009, 10, 19–24.
  • Xu Y, Hanna MA: ‘Electrosprayed bovine serum albumin-loadedtripolyphosphate cross-linked chitosan capsules: synthesis and characterization’,J.Microencapsulation, 2007, 24, 143–151.
  • Xu Y, Skotak M, Hanna M: ‘Electrospray encapsulation of water-solubleprotein with polylactide. I. Effects of formulations and process on morphologyand particle size’,J. Microencapsulation, 2006, 23, 69–78.
  • Pancholi K, Ahras N, Stride E, Edirisinghe M: ‘Novel electrohydrodynamic preparationof porous chitosan particles for drug delivery’,J.Mater. Sci., Mater. Med., 2009, 20, 917–923.
  • Enayati M, Ahmad Z, Stride E, Edirisinghe M: ‘Size mapping of electric field-assistedproduction of polycaprolactone particles’,Curr.Pharm. Biotechnol., 2009, 10, 600–608.
  • Jose GR, Park K: ‘Oral drug delivery: prospects and challenges’,J.Drug Delivery Sci. Technol., 2004, 4, 1–7.
  • Langer R: ‘Perspectives: drug delivery–drugson target’,Science, 2001, 293, 58–59.
  • Enayati M, Ahmad Z, Stride E, Edirisinghe M: ‘One step electrohydrodynamic productionof drug-loaded micro- and nano-particles’,J.R. Soc. Interface, 2009, 1, 1–9.
  • Bajaj A, Desai M: ‘Challenges and strategies in noveldrug delivery technologies’,Pharma Times, 2006, 38, 12–16.
  • Enayati M, Chang MW, Bragman F, Edirisinghe M, Stride E: ‘Electrohydrodynamic preparation ofparticles, capsules and bubbles for biomedical engineering applications,ColloidsSurf. A, 2011, 382A, 154–164.
  • Mathiowitz E, ed (ed.): ‘Encyclopaedia of controlleddrug delivery; 1999, New York, JohnWiley.
  • Ratner BD, Hoffman AS, Schoen FJ, Lemons (eds.) JE: ‘Biomaterials science. An introductionto materials in medicine’, 2nd edn; 2004, SanDiego, CA, Academic Press.
  • Higuchi T: ‘Mechanisms of sustained action mediation:theoretical analysis of rate of release of solid drugs dispersed in solidmatrices’,J. Pharm. Sci., 1963, 52, 1143–1149.
  • Balmayor ER, Baran ET, Azevedoa HS, Reis RL: ‘Injectable biodegradable starch/chitosandelivery system for the sustained release of gentamicin to treat bone infections’, Carbohyd.Polym., 2011, to be published.
  • Bohner M, Van Landuyt P, Merkle HP, Lemaitre J: ‘Composition effects on the pH of ahydraulic calcium phosphate cement’,J. Mater.Sci., Mater. Med., 1997, 8, 675–681.
  • Bohner M, Lemaitre J, Ring TA: Effects of sulfate, pyrophosphate, and citrateions on the physicochemical properties of cements made of β-tricalciumphosphate-phosphoric acid–water mixtures,J.Am. Ceram. Soc., 1996, 79, 1427–1434.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.